Abstract
Neuroblastoma (NB), an embryonal tumor derived from the neural crest, originates from sympathetic nerve system, manifests as thoracic, paraspinous or abdominal tumors, and metastases to bone in high-risk cases. Although NB stands as the most common solid tumor in early childhood and accounts for about 15 % of total pediatric cancer death, there has been limited success in searching for novel therapeutic regimen for this lethal disease during the past two decades. Numerous epidemiological and clinical studies have pinpointed anaplastic lymphoma kinase (ALK) and MYCN as potent governors for NB malignant behavior. ALK and MYCN amplification and constitutive active mutations are common in high-risk NB patients. However, there is still lack of evidence showing that a small molecule compound could simultaneously inhibits ALK and MYCN and plays strong negative regulatory roles in NB. Here, we showed that 17-DMAG, a well-known HSP-90 inhibitor, significantly inhibits NB cell growth, arrests cell cycle, and strongly induces NB cell apoptosis. Interestingly, our data suggests that NB cells with both ALK and MYCN amplification/mutation are more sensitive to 17-DMAG treatment, while NB cells with only ALK or MYCN amplification are less sensitive and NB cells without ALK or MYCN amplification/mutation are least sensitive. Moreover, we also found that knocking down ALK and MYCN additively inhibits NB cell growth and that transduction of MYCN largely abolished the ALK-dependent NB cell growth, indicating that there is a cross-talk between MYCN and ALK signaling machinery. Our results provide proof-of-principle that 17-DMAG strongly inhibits NB cell growth by targeting both ALK and MYCN. Our findings might shed a light for further investigation of novel small molecule compound which is safe and exerts similar strong effects in vivo as novel approaches for management of high-risk NB.
Similar content being viewed by others
References
Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10:4–12.
Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest. 1996;75:659–75.
Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol. 2001;54:897–910.
Maris JM. Recent advances in neuroblastoma. New Engl J Med. 2010;362:2202–11.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–97.
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. New Engl J Med. 1999;341:1165–73.
Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene n-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A. 1984;81:4940–4.
Schwab M. Mycn in neuronal tumours. Cancer Lett. 2004;204:179–87.
Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The mycn oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011;21:256–66.
Dang CV. Myc on the path to cancer. Cell. 2012;149:22–35.
George RE, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J, et al. Activating mutations in alk provide a therapeutic target in neuroblastoma. Nature. 2008;455:975–8.
Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of alk as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5.
Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the alk kinase receptor in neuroblastoma. Nature. 2008;455:967–70.
Azarova AM, Gautam G, George RE. Emerging importance of alk in neuroblastoma. Semin Cancer Biol. 2011;21:267–75.
Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of alk kinase in neuroblastoma. Nature. 2008;455:971–4.
Ogawa S, Takita J, Sanada M, Hayashi Y. Oncogenic mutations of alk in neuroblastoma. Cancer Sci. 2011;102:302–8.
Carpenter EL, Mosse YP. Targeting alk in neuroblastoma—preclinical and clinical advancements. Nat Rev Clin Oncol. 2012;9:391–9.
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, et al. Meta-analysis of neuroblastomas reveals a skewed alk mutation spectrum in tumors with mycn amplification. Clin Cancer Res. 2010;16:4353–62.
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The alk(f1174l) mutation potentiates the oncogenic activity of mycn in neuroblastoma. Cancer Cell. 2012;22:117–30.
Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, et al. Activated alk collaborates with mycn in neuroblastoma pathogenesis. Cancer Cell. 2012;21:362–73.
Schonherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, et al. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of mycn in neuroblastoma cells. Oncogene. 2012;31:5193–200.
Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-dmag) given intravenously to patients with advanced solid tumors. Clin Cancer Res. 2011;17:1561–70.
Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-dmag, on non-small-cell lung cancers being resistant to egfr tyrosine kinase inhibitor. Lung Cancer. 2012;75:161–6.
Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 2005;56:115–25.
Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, et al. Stage 1 testing and pharmacodynamic evaluation of the hsp90 inhibitor alvespimycin (17-dmag, kos-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;51:34–41.
Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (kos-1022; 17 dmag) in the treatment of advanced solid tumors. Clin Cancer Res. 2012;18:5090–8.
Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, et al. Hsp90 inhibition increases p53 expression and destabilizes mycn and myc in neuroblastoma. Int J Oncol. 2011;38:105–12.
Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, et al. Inhibition of alk, pi3k/mek, and hsp90 in murine lung adenocarcinoma induced by eml4-alk fusion oncogene. Cancer Res. 2010;70:9827–36.
Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411.
Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, et al. Mycn and alkf1174l are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene. 2013;32:1059–65.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplemental Fig. 1
Western blots of cell cycle markers CDK1 and Cyclin B1 confirmed that 17-DMAG treatment in NB cell lines caused cell cycle arrest. GOTO, CHP-134, KELLY and NB-1 cells were treated with 0 (Veh) or 0.15 μM 17-DMAG (DMA) for 24 hours and protein lysates were subjected to immunoblot analysis with the indicated antibodies. (JPEG 8 kb)
Supplemental Fig. 2
17-DMAG mildly decreased HSP90 expression in NB cell lines. GOTO, CHP-134, KELLY and NB-1 cells were treated with 0 (Veh) or 0.15 μM 17-DMAG for 24 h and were subjected to ELISA analysis. Statistically significant differences compared to the corresponding data for vehicle of each cell line were shown (*p < 0.05). Data shown are the mean values (±SE) from three independent experiments. (JPEG 44 kb)
Supplemental Table 1
(DOC 32 kb)
Rights and permissions
About this article
Cite this article
Yi, B., Yang, J. & Wang, L. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line. Tumor Biol. 35, 3229–3235 (2014). https://doi.org/10.1007/s13277-013-1422-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-1422-7